×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRK – merck & company, inc. (new) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/6
06:45 am
mrk
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
12/31
07:29 am
mrk
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% [Yahoo! Finance]
Low
Report
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% [Yahoo! Finance]
12/30
07:16 pm
mrk
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]
Low
Report
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]
12/27
12:45 pm
mrk
U.S. FDA approves injectable version of cancer drug from Bristol Myers Squibb [Globe and Mail, The (Toronto, Canada)]
Low
Report
U.S. FDA approves injectable version of cancer drug from Bristol Myers Squibb [Globe and Mail, The (Toronto, Canada)]
12/27
07:34 am
mrk
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? [Yahoo! Finance]
Low
Report
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? [Yahoo! Finance]
12/27
04:26 am
mrk
Animal Parasiticides Market Worth $15.83 Billion by 2032: An Analysis of Revenue and % Shares by Type, Animal, End User, Country, and Company [Yahoo! Finance]
Low
Report
Animal Parasiticides Market Worth $15.83 Billion by 2032: An Analysis of Revenue and % Shares by Type, Animal, End User, Country, and Company [Yahoo! Finance]
12/26
10:03 am
mrk
2 Reasons to Sell Merck Stock and 1 Reason to Buy [Yahoo! Finance]
Low
Report
2 Reasons to Sell Merck Stock and 1 Reason to Buy [Yahoo! Finance]
12/24
07:41 pm
mrk
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing [Yahoo! Finance]
Low
Report
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
-3.4%
merck & company, inc. (new)
7/30/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
-10.9%
merck & company, inc. (new)
4/25/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
2.5%
merck & company, inc. (new)
2/1/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
4.7%
merck & company, inc. (new)
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/3
01:57 pm
mrk
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Seidman Christine E
Low
Report
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Seidman Christine E
1/3
01:55 pm
mrk
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: GLOCER THOMAS H
Low
Report
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: GLOCER THOMAS H
1/3
01:53 pm
mrk
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Coe Mary Ellen
Low
Report
Form 4 Merck & Co., Inc. For: Dec 31 Filed by: Coe Mary Ellen
1/3
12:59 pm
mrk
Form 4 Merck & Co., Inc. For: Jan 01 Filed by: Karsanbhai Surendralal Lanca
Low
Report
Form 4 Merck & Co., Inc. For: Jan 01 Filed by: Karsanbhai Surendralal Lanca
1/3
12:55 pm
mrk
Form 3 Merck & Co., Inc. For: Jan 01 Filed by: Karsanbhai Surendralal Lanca
Low
Report
Form 3 Merck & Co., Inc. For: Jan 01 Filed by: Karsanbhai Surendralal Lanca
11/22
02:28 pm
mrk
Form 8-K Merck & Co., Inc. For: Nov 19
Low
Report
Form 8-K Merck & Co., Inc. For: Nov 19
11/6
04:06 pm
mrk
Form 10-Q Merck & Co., Inc. For: Sep 30
Low
Report
Form 10-Q Merck & Co., Inc. For: Sep 30
11/4
10:06 am
mrk
Form 25-NSE Merck & Co., Inc. Filed by: NEW YORK STOCK EXCHANGE LLC
Low
Report
Form 25-NSE Merck & Co., Inc. Filed by: NEW YORK STOCK EXCHANGE LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
TOP News Decliners
3/13
Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily]
-8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: